MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 138 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 2.24 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $37,000 | -59.8% | 30,000 | 0.0% | 0.01% | -60.0% |
| Q1 2017 | $92,000 | -24.6% | 30,000 | 0.0% | 0.02% | -21.1% |
| Q4 2016 | $122,000 | -36.1% | 30,000 | 0.0% | 0.02% | -34.5% |
| Q3 2016 | $191,000 | +17.9% | 30,000 | 0.0% | 0.03% | +26.1% |
| Q2 2016 | $162,000 | -35.5% | 30,000 | 0.0% | 0.02% | -34.3% |
| Q1 2016 | $251,000 | +5.9% | 30,000 | 0.0% | 0.04% | +6.1% |
| Q4 2015 | $237,000 | -7.1% | 30,000 | 0.0% | 0.03% | -23.3% |
| Q3 2015 | $255,000 | -31.3% | 30,000 | 0.0% | 0.04% | -27.1% |
| Q2 2015 | $371,000 | +4.2% | 30,000 | 0.0% | 0.06% | +5.4% |
| Q1 2015 | $356,000 | +5.0% | 30,000 | 0.0% | 0.06% | +33.3% |
| Q4 2014 | $339,000 | +28.9% | 30,000 | 0.0% | 0.04% | +20.0% |
| Q3 2014 | $263,000 | +20.1% | 30,000 | 0.0% | 0.04% | +20.7% |
| Q2 2014 | $219,000 | +45.0% | 30,000 | 0.0% | 0.03% | +20.8% |
| Q1 2014 | $151,000 | -5.6% | 30,000 | 0.0% | 0.02% | -4.0% |
| Q4 2013 | $160,000 | – | 30,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
| Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
| Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
| INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
| GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
| Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
| Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
| LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
| STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |